Big Breaking News This Morning Has Allied Corp. (ALID) Up Approximately 15% Early
ALID dropped some game-changing news this morning. Read it here:
Allied Sells Out First Colombian Harvest and Begins to Rapidly Scale Colombian Production
KELOWNA, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce that it has sold out of its first harvest production inventory.
The demand for Allied’s high quality product has surpassed Allied’s initial supply. In response to this, Allied is swiftly scaling the production in Colombia.
Allied has signed the last purchase order from an international buyer that completes the sale of the last volume of production output from Allied’s initial harvest. This news comes as follow up to Allied’s approvals for being able to commercialize its production output as well as approvals to export to two very large international markets. This positive response from the market has enabled Allied to expedite its business plan.
Scaling the Colombian Production Center
Allied has now prepared the cultivation site and required infrastructure to be able to have the current site operating at full capacity. Allied intends to further expand this to include the additional land surrounding its current location. Due to the advantages that the equatorial climate offers, Allied has adopted a weekly rolling harvest schedule. This presents consistent reliable supply at national level volumes. With the current export approvals, Allied can supply national level quantities to wholesale buyers in several international markets.
“Like in any healthy market, good quality product moves very quickly. We have been very purposeful to not expand too quickly but rather match our supply to the market demand. In light of this, we have put resources towards scaling the production footprint in Colombia. 2021 is an exciting year thus far for Allied to say the least,” said Calum Hughes CEO of Allied.
Read the full article here.
With this huge news, ALID is currently up approximately 15% and could be gaining steam towards a potential breakout.
Drop what you're doing right now, read the initial report below, and get ALID on your radar.
For over two years now, the FDA has been fast-tracking psi-lo-cybin for treatment of PTSD.
Psych-e-delic pharmaceuticals coupled with pharmaceutical can-na-bis is now projected to grow at an astonishing 30-fold growth rate approaching $60Bn this decade!
One company, Allied Corp. (OTCQB: ALID), is uniquely positioned to take a commanding lead in the supply chain for this emerging multi-Bn-dollar market.
Today, a new trend is building as psi-lo-cybin enters as a complement to the already launched medical movement for can-na-bis-sourced pharmaceutical compounds. What you’re about to learn is that after years of clinical study, psi-lo-cybin is now being hailed for newly discovered pharmaceutical uses.
In fact, the FDA could be only months away from a breakthrough announcement that puts psi-lo-cybin on the approved formularies list for the treatment of serious mental disorders.
The Starting Block That Launches Massive Opportunities in the Combined Psych-e-delics and Can-na-bis Sector
This is a new frontier, and it is loaded with potential opportunities.
Psi-lo-cybin, found in a unique species of mush-rooms, is the latest plant-based organic compound researchers are proving to be powerfully effective in therapies for treating PTSD, opioid addictions, alcoholism and chronic depression/anxiety disorders.
In the United States, projections are that the pharmaceutical uses for once vilified psych-e-delic and can-na-bis compounds could soar to approach a massive $60Bn market size by the end of this decade.
In this report, you will learn about one company, Allied Corp. (OTCQB: ALID), which is uniquely positioned to take a commanding position in the supply chain for this emerging multi-Bn-dollar market.
Allied Files Provisional Patent for Psi-lo-cybin Therapeutic Invention Seeking Drug Indication for Mental Health Depression and Anxiety Applications
Psych-e-delics Is a Packed Sector… and It’s Only the Beginning
Today, psych-e-delic pharmacology coupled with the also emerging market for can-na-binoid pharmaceuticals, is breaking never-before-seen ground.
As I stated above, forecasts are that this sector will rocket from where it is today to a figure approaching $60Bn this decade!
That’s roughly 30-fold growth!
After a year of following and studying this trend, I believe that now is definitely the time to watch Allied closely.
Before you do, make note of this: that $60Bn figure could be the tip of the iceberg.
In 2018, Catalyze.org reported that…
“The U.S. spends over $200Bn on mental health disorders, ranking it as one of the costliest areas of health care, even above heart conditions and trauma and injury. When you consider the prevalence of depression, stress, anxiety, and substance use disorders, this may not be surprising. 18% of Americans have a mental health condition.” 
Globally, I believe this figure could be projected into the trill-ions of dollars!
In the end, the top-performing companies in this emerging sector must be capable of quickly and effectively scaling operations to the massive growth seen emerging in this market.
If you share my enthusiasm for this opportunity, then I strongly recommend that you move quickly to get Allied Corp. (OTCQB: ALID) on your radar.
Years ago, Allied management saw this market emerging and began strategic preparations for becoming one of the world’s top suppliers of high-grade psych-e-delic and cann-a-bis compounds for both the direct-to-consumer market and to the pharmaceutical industry.
Their vision has been profoundly prescient. Allied has since grown to international scale with connections and operations that extend from Colombia, South America, to Mexico, the United States and Canada.
In addition to its burgeoning consumer products division, it is now fully prepared to become one of the world leaders in supplying critically needed cann-a-binoids and psych-e-delic compounds to the pharmaceutical industry.
Fulfillment of a Long-Term Vision That Could Propel Allied to Global Leadership
- Allied Corp. (OTCQB: ALID) reports it is fully capable of scaling operations as a single-source, vertically oriented supplier of cann-a-binoid and psych-e-delic compounds (as legislation allows) soon to flow into the pharmaceutical industry.
- These compounds will be essential to the pharmaceutical industry in the face of massive markets likely to follow projected FDA approvals.
- Today, Allied is one of the only companies in the world prepared to use its unique international supply-chain network to meet the anticipated needs of this emerging pharmaceutical industry.
- At present, Allied may be trading at a fraction of what its longer-term potential holds.
Allied is entering the most transformative phase of its long-term growth plans… generating revenue as well as pro-fit-ability is in their plan, as reported in their most recent in-vestor presentation!
More than anything, this can put Allied on radar screens.